Latest news newssearch boxGO All Ad hoc Other 06 Sep 2023 Idorsia reacquires the world-wide rights to aprocitentan 25 Jul 2023 Idorsia announces financial results for the first half 2023 – adapting the company to create sustainable value 21 Jul 2023 Idorsia announces a cost reduction initiative to be implemented by the end of 2023 20 Jul 2023 Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF 400 million 18 Jul 2023 Invitation to Idorsia's HY 2023 Financial Results webcast and conference call 10 Jul 2023 Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now covered by CVS 26 Jun 2023 New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the European Society of Hypertension Annual Meeting 2023 23 Jun 2023 New Phase 3 data with aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2023 20 Jun 2023 Idorsia has secured bridge financing in the amount of CHF 75 million 12 Jun 2023 Idorsia launches QUVIVIQ (daridorexant) in Switzerland – a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning 06 Jun 2023 Idorsia has entered into exclusive negotiations with regard to a prospective strategic transaction for its Asia Pacific (ex-China) operations for up to CHF 400 million 30 May 2023 Idorsia announces a change to commercial leadership 04 May 2023 Idorsia holds its Annual General Meeting of Shareholders 03 May 2023 Health Canada approves QUVIVIQ (daridorexant) for the management of adult patients with insomnia 25 Apr 2023 Idorsia announces financial results for the first quarter 2023 – QUVIVIQ now the leading branded insomnia medicine in the commercial market in the US 06 Apr 2023 Idorsia issues invitation to the 2023 Annual General Meeting of Shareholders 17 Mar 2023 On World Sleep Day Idorsia highlights the publication of a global study on the economic and societal impact of chronic insomnia disorder 07 Feb 2023 Idorsia announces financial results for 2022 – building momentum to become a leading mid-sized biopharmaceutical company 06 Feb 2023 Idorsia announces the results of REACT a Phase 3 study of clazosentan in patients following aneurysmal subarachnoid hemorrhage 31 Jan 2023 Idorsia submits European marketing authorisation application for aprocitentan for the treatment of patients with resistant hypertension 1 2 3 4 5 6 7 8
Ad hoc announcements pursuant to Art. 53 LR Ad hoc announcements pursuant to Art. 53 LR have been classified from 2021 onwards. A full archive of press releases can be found under the "All" tab.